These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38755140)

  • 21. Chromosome 1q21 abnormalities in multiple myeloma.
    Schmidt TM; Fonseca R; Usmani SZ
    Blood Cancer J; 2021 Apr; 11(4):83. PubMed ID: 33927196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.
    Tirier SM; Mallm JP; Steiger S; Poos AM; Awwad MHS; Giesen N; Casiraghi N; Susak H; Bauer K; Baumann A; John L; Seckinger A; Hose D; Müller-Tidow C; Goldschmidt H; Stegle O; Hundemer M; Weinhold N; Raab MS; Rippe K
    Nat Commun; 2021 Nov; 12(1):6960. PubMed ID: 34845188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
    D'Agostino M; Rota-Scalabrini D; Belotti A; Bertamini L; Arigoni M; De Sabbata G; Pietrantuono G; Pascarella A; Tosi P; Pisani F; Pescosta N; Ruggeri M; Rogers J; Olivero M; Garzia M; Galieni P; Annibali O; Monaco F; Liberati AM; Palmieri S; Stefanoni P; Zamagni E; Bruno B; Calogero RA; Boccadoro M; Musto P; Gay F
    Blood Cancer J; 2024 Jun; 14(1):94. PubMed ID: 38849344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PHF19 inhibition as a therapeutic target in multiple myeloma.
    Schinke CD; Bird JT; Qu P; Yaccoby S; Lyzogubov VV; Shelton R; Ling W; Boyle EM; Deshpande S; Byrum SD; Washam C; Mackintosh S; Stephens O; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Barlogie B; van Rhee F; Walker BA
    Curr Res Transl Med; 2021 Jul; 69(3):103290. PubMed ID: 33894670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
    Jiang H; Gao W; Sze DM; Xiong H; Hou J
    Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
    Yang WC; Lin SF
    Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.
    Lazzari E; Mondala PK; Santos ND; Miller AC; Pineda G; Jiang Q; Leu H; Ali SA; Ganesan AP; Wu CN; Costello C; Minden M; Chiaramonte R; Stewart AK; Crews LA; Jamieson CHM
    Nat Commun; 2017 Dec; 8(1):1922. PubMed ID: 29203771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
    Giesen N; Paramasivam N; Toprak UH; Huebschmann D; Xu J; Uhrig S; Samur M; Bähr S; Fröhlich M; Mughal SS; Mai EK; Jauch A; Müller-Tidow C; Brors B; Munshi N; Goldschmidt H; Weinhold N; Schlesner M; Raab MS
    Haematologica; 2022 Aug; 107(8):1891-1901. PubMed ID: 35045690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum and functional validation of PSMB5 mutations in multiple myeloma.
    Barrio S; Stühmer T; Da-Viá M; Barrio-Garcia C; Lehners N; Besse A; Cuenca I; Garitano-Trojaola A; Fink S; Leich E; Chatterjee M; Driessen C; Martinez-Lopez J; Rosenwald A; Beckmann R; Bargou RC; Braggio E; Stewart AK; Raab MS; Einsele H; Kortüm KM
    Leukemia; 2019 Feb; 33(2):447-456. PubMed ID: 30026573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
    Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
    Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
    Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.
    Jirabanditsakul C; Dakeng S; Kunacheewa C; U-Pratya Y; Owattanapanich W
    Technol Cancer Res Treat; 2022; 21():15330338221111228. PubMed ID: 35770320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
    Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
    Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
    Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
    Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
    Kassambara A; Schoenhals M; Moreaux J; Veyrune JL; Rème T; Goldschmidt H; Hose D; Klein B
    PLoS One; 2013; 8(4):e62752. PubMed ID: 23646139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
    Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM; Boise LH
    Nat Commun; 2019 Apr; 10(1):1911. PubMed ID: 31015454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
    Vo JN; Wu YM; Mishler J; Hall S; Mannan R; Wang L; Ning Y; Zhou J; Hopkins AC; Estill JC; Chan WKB; Yesil J; Cao X; Rao A; Tsodikov A; Talpaz M; Cole CE; Ye JC; ; Bergsagel PL; Auclair D; Cho HJ; Robinson DR; Chinnaiyan AM
    Nat Commun; 2022 Jun; 13(1):3750. PubMed ID: 35768438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.